The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Growth In Market Value Is Anticipated For The Liquid Biopsy For Cancer Diagnostics Market Between 2026 And 2030?
The liquid biopsy for cancer diagnostics market size has experienced rapid growth in recent years. This market is set to expand from $10.75 billion in 2025 to $12.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.4%. Historically, this growth has been fueled by limitations associated with tissue biopsy procedures, the increasing incidence of lung and breast cancer, the early adoption of molecular cancer diagnostics, a growing need for early-stage cancer detection, and rising clinical research in oncology diagnostics.
The liquid biopsy for cancer diagnostics market size is anticipated to experience substantial growth over the coming years. It is projected to expand to $22.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.4%. This expansion during the forecast period can be attributed to several factors, including the wider implementation of liquid biopsy in routine cancer screening, an increasing emphasis on personalized cancer care, its growing use in monitoring treatment responses, rising investments in cancer diagnostics, and its expanded application in gastrointestinal and ovarian cancers. Prominent trends expected in this period include the increased adoption of liquid biopsy for lung cancer diagnosis, a surge in the use of blood-based cancer screening methods, a heightened demand for real-time cancer monitoring, the broadening application of liquid biopsy across various cancer types, and a growing clinical preference for minimally invasive diagnostic approaches.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp
What Market Drivers Are Helping Shape The Liquid Biopsy For Cancer Diagnostics Market Expansion?
The increasing prevalence of cancer is anticipated to fuel the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer, a wide range of diseases, occurs when abnormal cells multiply uncontrollably in almost any body organ or tissue, exceeding their normal limits and either spreading to other areas or invading adjacent tissues. This condition heightens the demand for diagnostic methods like early detection of cancer or tumor recurrence, patient-specific risk evaluation, and treatment monitoring, allowing liquid biopsy to present a comprehensive view of the disease. This is because tumor cells or their products are released from all primary or metastatic tumor sites, offering detailed and current insights into tumor progression, therapeutic targets, and mechanisms of treatment resistance. For example, as reported by the National Cancer Institute, a US government body, in May 2024, approximately 18.1 million cancer survivors were in the United States. This number is predicted to grow to 22.5 million by 2032. Furthermore, by 2040, annual new cancer cases are projected to hit 29.9 million, with cancer-related fatalities expected to climb to 15.3 million. Consequently, the escalating incidence of cancer is boosting the growth of the liquid biopsy for cancer diagnostics market.
What Segment Categories Are Evaluated In The Liquid Biopsy For Cancer Diagnostics Market Study?
The liquid biopsy for cancer diagnostics market covered in this report is segmented –
1) By Type: Product, Services
2) By Sample: Blood, Urine, Saliva
3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices
2) By Services: Testing Services, Analytical Services, Bioinformatics Services
What Trends Are Driving Changes In The Liquid Biopsy For Cancer Diagnostics Market?
Major companies operating in the liquid biopsy for cancer diagnostics market are focusing their initiatives on developing innovative solutions, including advanced liquid biopsy assays. Such an assay is a sophisticated diagnostic test designed to analyze various components in a liquid biological sample, like blood or other bodily fluids, to detect and characterize specific biomarkers associated with cancer or other diseases. As an illustration, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, announced the launch of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This product is a research assay created to enable noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) sourced from blood. The TSO 500 ctDNA v2 assay aims to simplify user integration and enhance the depth of insights obtainable for cancer research.
Which Companies Form The Competitive Landscape Of The Liquid Biopsy For Cancer Diagnostics Market?
Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC
Access The Complete Liquid Biopsy For Cancer Diagnostics Market Report:
Which Region Stands As The Largest Contributor To The Liquid Biopsy For Cancer Diagnostics Market?
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Liquid Biopsy For Cancer Diagnostics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp
Browse Through More Reports Similar to the Global Liquid Biopsy For Cancer Diagnostics Market 2026, By The Business Research Company
Liquid Biopsy For Cancer Diagnostics Global Market Report 2026
Biopsy Devices Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report
Biopsy Devices Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model